Original Title: Notice on Issuing the "Several Policies for Accelerating the High-Quality Development of the Biopharmaceutical and Life Sciences Industry in Baoshan District"
Baojing Gui [2022] No. 2
To the People’s Governments of All Towns, Subdistrict Offices, and All Commissions, Offices, and Bureaus of the District Government:
To further advance the strategic positioning of “building the main hub of Shanghai’s science and technology innovation center,” accelerate the strategic planning and layout of the biopharmaceutical industry, and promote the high-quality development of Baoshan District’s biopharmaceutical industry, the “Several Policies of Baoshan District on Accelerating the High-Quality Development of the Biopharmaceutical and Life Sciences Industry” have been formulated and approved by the District Government. This document is hereby issued to you; please implement it conscientiously.
Shanghai Baoshan District Economic Commission
Office of the Leading Group for Talent Work of Baoshan District, Shanghai
Shanghai Baoshan District Development and Reform Commission
Shanghai Baoshan District Science and Technology Commission
Shanghai Baoshan District State-owned Assets Supervision and Administration Commission
Shanghai Baoshan District Health Commission
Shanghai Baoshan District Science and Technology Innovation Development and Management Commission
Shanghai Baoshan District Human Resources and Social Security Bureau
Shanghai Baoshan District Medical Security Bureau
Shanghai Baoshan District Bureau of Ecology and Environment
Shanghai Baoshan District Housing Security and Housing Administration Bureau
Shanghai Baoshan District Market Supervision Administration
Shanghai Wusong Customs of the People's Republic of China
August 19, 2022
Several Policies of Baoshan District to Accelerate the High-Quality Development of the Biopharmaceutical and Life Sciences Industries
To further advance the strategic positioning of “building the main hub of Shanghai’s science and technology innovation center,” promote transformative development, and accelerate the strategic planning and layout of the biopharmaceutical industry, in accordance with the spirit of the “Several Opinions on Promoting the High-Quality Development of the City’s Biopharmaceutical Industry” (Shanghai Municipal Government Office Regulation [2021] No. 5) and the “Implementation Opinions on Accelerating the Transformative Development of the North and South Regions” (Shanghai Municipal Government Document [2022] No. 5),to advance the high-quality development of the biopharmaceutical industry in Baoshan District and build a new hub for the biopharmaceutical industry with the distinctive characteristics of Northern Shanghai, these policies are hereby formulated.
I. General Provisions
(1) Main Objectives: Focus on distinctive and advantageous sectors, strengthen innovation hubs, and expand the scale of the industry. Building upon the North Shanghai Biomedical Industrial Park, the policy aims to attract and develop a group of “chain-leading” enterprises, construct a full-chain ecosystem for the biomedical industry, and foster a new phase of high-quality development characterized by efficient synergy.
(2) Supported Fields
Pharmaceuticals: Prioritize support for green, innovative chemical drugs with high clinical value; high-end biological products such as gene therapy, cell therapy, antibody drugs, and innovative vaccines; as well as novel drug formulations and modern traditional Chinese medicine. Promote the full-chain development of pharmaceutical R&D, pilot-scale incubation, industrialization, and CRO/CDMO services.
Medical Device Sector: Focus on the R&D and industrialization of innovative medical devices, including in vitro diagnostic equipment and reagents, medical imaging equipment, implantable and interventional medical devices, medical and rehabilitation robots, biochips, and eco-friendly biomedical materials.
Pharmaceutical and Medical Device Equipment Sector: Support technological innovation, high-end manufacturing, and industrial applications of pharmaceutical and medical device equipment to further enhance production efficiency and advance digitalization, intelligentization, and integration. Encourage the integration of equipment manufacturing with Process Analytical Technology (PAT) and promote domestic substitution for animal cell culture media and single-use bioreactor bags.
Healthcare Services Sector: Explore new healthcare service models oriented toward “precision, digitization, intelligence, and integration,” and strengthen breakthroughs in cutting-edge technologies such as next-generation sequencing, biological big data, gene editing, synthetic biology, and regenerative medicine, as well as the cultivation of disruptive innovations.
(3) Scope of Application This document applies to enterprises, public institutions, social organizations, private non-enterprise entities, and other organizations registered within the Baoshan district that possess independent legal person status and are engaged in pharmaceuticals, medical devices, pharmaceutical and medical device equipment, or medical services.
II. Support Policies
(1) Supporting the Establishment of Leading Enterprises and High-Quality Projects
1. Support for the Establishment of Corporate Headquarters and R&D Centers. Focusing on industry leaders and chain-leading enterprises, the following startup funding support will be provided to companies listed in the Fortune Global 500, the Global Top 50 Pharmaceutical Companies, the Top 100 Chinese Pharmaceutical Companies, and “chain-leading” enterprises in the biopharmaceutical and life sciences sectors that establish headquarters in our district: up to 80 million yuan, 60 million yuan, 40 million yuan, and 20 million yuan per enterprise, respectively;For enterprises of the aforementioned categories that establish R&D centers with independent legal person status in our district, start-up funding support of up to 20 million yuan, 10 million yuan, 5 million yuan, and 2 million yuan will be provided, respectively. The above funding support measures are not cumulative.
2. Accelerate the implementation of industrialization projects. Support newly introduced biopharmaceutical and life sciences projects that play a pivotal role in driving overall development and serve as major industry leaders, particularly those that have obtained drug registration approvals or innovative medical device product registration certificates in our district and are implementing industrialization here. Support will be provided at 20% of the project’s total fixed-asset investment, up to a maximum of 50 million yuan; for newly introduced special major projects with a total investment exceeding 5 billion yuan, support may be increased.
3. Encourage enterprises following the “Zhangjiang R&D + Shanghai Manufacturing” model to establish operations in Baoshan. For industrialization projects meeting the “Zhangjiang R&D + Shanghai Manufacturing” criteria that have been approved for Zhangjiang special funds, support will be provided at both the municipal and district levels, with a maximum of 40 million yuan per enterprise.
4. Secure land for industrial projects. For high-quality biopharmaceutical and life sciences projects, industrial land will be granted on a flexible lease term of 20 to 50 years; when arranging annual land use plans, priority will be given to meeting the new construction land needs of such projects.
5. Reducing Land Costs. For high-quality biopharmaceutical and life sciences projects that meet the eligibility criteria, support will be provided in the form of a 30% discount on the appraised value of industrial land (not less than the benchmark price for industrial land).
(II) Supporting the Industry to Become More Competitive and Stronger
6. Encouraging Enterprises to Grow Larger and Stronger
(1) A one-time reward of 5 million yuan will be granted to enterprises in our district that enter the Top 100 Chinese Pharmaceutical Industry List for the first time.
(2) For enterprises whose annual main business revenue in the district first exceeds 50 million yuan, 100 million yuan, 200 million yuan, or 300 million yuan, a maximum reward of 200,000 yuan, 300,000 yuan, 400,000 yuan, or 500,000 yuan, respectively, shall be granted; after annual main business revenue exceeds 300 million yuan, a one-time reward of 500,000 yuan shall be granted for every additional 300 million yuan (i.e., a one-time reward of 500,000 yuan shall be granted upon first exceeding 600 million yuan, 900 million yuan, and so on).In principle, the annual reward for a single legal entity shall not exceed 1 million yuan.
7. Encouraging Contract Manufacturing
(1) For holders of marketing authorizations for drugs or medical devices within Baoshan District who commission local biopharmaceutical enterprises (provided there is no investment relationship between the commissioning party and the contractor) to provide manufacturing services, the commissioning party will receive support equivalent to 5% of the contract value for the first transaction of a single product, up to a maximum of 5 million yuan. The annual support limit for a single enterprise (or institution) is 10 million yuan.
(2) For holders of marketing authorizations for pharmaceuticals or medical devices within Baoshan District who commission local biopharmaceutical enterprises (where there is no investment relationship between the commissioning and commissioned parties) to manufacture their products, the commissioned party shall receive support equivalent to 20% of the contract value for the first transaction of a single product, up to a maximum of 15 million yuan; the annual maximum for a single enterprise is 30 million yuan;For enterprises (or institutions) outside the district that commission local biopharmaceutical enterprises to manufacture their products, the contractor shall receive support equivalent to 5% of the contract value for the first transaction of a single product, up to a maximum of 5 million yuan, with a maximum of 10 million yuan per enterprise per year.
8. Encourage enterprises to undergo digital transformation and upgrading. Support enterprises in actively utilizing technologies such as industrial internet, big data, and artificial intelligence to achieve digital transformation and upgrading. For projects listed as municipal-level demonstration applications, provide support of up to 30 million yuan; for projects listed as municipal-level benchmark unmanned factories, unmanned production lines, or unmanned workshops, provide support of up to 5 million yuan.
9. Encourage enterprises to participate in national centralized procurement of pharmaceuticals and medical devices. For selected pharmaceuticals, a 5% reward based on the annual centralized procurement payment will be provided, with a maximum subsidy of 2 million yuan per enterprise; for selected medical devices, a 3% reward based on the annual centralized procurement payment will be provided, with a maximum subsidy of 1 million yuan per enterprise.
10. Support enterprises in expanding their international business. A reward of 200,000 yuan will be granted to enterprises whose annual export volume reaches 1 million USD for the first time; an additional 100,000 yuan will be awarded for every subsequent increase of 100,000 USD, with a maximum annual reward of 2 million yuan per enterprise.
11. Support for enterprise IPO and financing. A one-time reward of 5 million yuan will be granted to biopharmaceutical and life sciences enterprises in this district that successfully list on domestic or international stock exchanges. A reward of up to 5 million yuan will be granted to listed companies relocating their headquarters from outside the district to this district.
(III) Strengthening Support for Innovation and R&D
12. Support for New Drug Development
(1) For projects that have secured national or municipal-level major special funding and are based in Baoshan, support will be provided at 50% of the actual municipal matching funds approved for national-level projects (or the actual support funds approved for municipal-level projects), up to a maximum of 15 million yuan.
(2) For new drugs undergoing clinical trials domestically or internationally and being commercialized in our district, funding will be provided in phases based on their R&D progress:
For innovative drugs that have completed Phase I or Phase II clinical trials, where the registration applicant in our district obtains approval and plans to manufacture the drug in our district, support will be provided at 40% of R&D investment, with a maximum of 10 million yuan and 30 million yuan, respectively, depending on the clinical trial phase;
For innovative drugs that have completed Phase III clinical trials, have obtained approval through a registration applicant in our district, and will be manufactured in our district, 40% of R&D expenditures will be supported, with a maximum of 50 million yuan;
For improved new drugs that have completed Phase II clinical trials, have been approved by a registration applicant in our district, and will be manufactured in our district, 20% of R&D expenditures will be subsidized, with a maximum support of 20 million yuan;
For improved new drugs that have completed Phase III clinical trials, for which a registration applicant in our district has obtained approval and which will be manufactured in our district, support of 20% of R&D expenditures will be provided, up to a maximum of 40 million yuan;
For projects receiving municipal-level funding at any of the above stages, matching support equal to 50% of the municipal funding will be provided. In principle, these policies are not cumulative.
(3) For companies that obtain a New Drug Production Approval or a Drug Marketing Authorization, a one-time grant of 5 million yuan will be provided for each approval (authorization); for marketed drugs that undergo further development to add new indications, support of up to 3 million yuan will be provided; the annual maximum support per enterprise is 12 million yuan.
13. Promote generic drug R&D. Enterprises that obtain a national first-generic drug production approval will receive a one-time grant of 5 million yuan; for other drugs (excluding first-generic drugs) that pass the generic drug bioequivalence evaluation, support of up to 4 million yuan will be provided; the annual cap per enterprise is 12 million yuan.
14. Encourage the overseas marketing of pharmaceuticals and medical devices. For innovative drugs and high-end medical devices developed and produced in Baoshan District that are approved for marketing by international agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), and are sold in relevant overseas markets, a one-time grant of 30% of R&D expenditures (up to 10 million yuan) will be provided upon selection and approval.For actual consulting fees, certification fees, and hardware/software investment costs (including initial certification, recertification, or expansion of certification scope), a single enterprise may receive up to 10 million yuan in support annually.
15. Support for Medical Device Development
(1) For enterprises engaged in medical device R&D, funding will be provided in phases based on their R&D progress:
For medical device products from this district that have entered the national or Shanghai municipal special review procedure for innovative medical devices, support of up to 3 million yuan will be provided;
For medical device products that have obtained a medical device registration certificate (Class III) for the first time and will be manufactured in our district, support of up to 40% of R&D expenditures, with a maximum of 6 million yuan, will be provided; For medical device products that have obtained a medical device registration certificate (Class II or other innovative products recognized by Shanghai Municipality) for the first time and are manufactured in our district, support of up to 20% of R&D expenditures, with a maximum of 3 million yuan, will be provided; the annual maximum for a single enterprise is 18 million yuan.
For projects receiving municipal-level funding support at any of the above stages, matching support equal to 50% of the municipal funding will be provided. In principle, these policies are not cumulative.
(2) For enterprises that obtain a Class III medical device manufacturing license, a one-time grant of up to 3 million yuan will be provided per license; the annual cap per enterprise is 6 million yuan.
16. Support the development of high-end medical device equipment and high-performance scientific research instruments. We encourage medical device equipment and instrument manufacturers in our district to undertake technological breakthroughs, improve product performance and precision, and collaborate with medical device enterprises on demonstration applications. For projects that enhance equipment production efficiency as well as digital and intelligent capabilities, and where the technical specifications of the relevant equipment and instruments meet the standards of imported counterparts, a maximum of 8 million yuan in support will be provided upon evaluation and approval.
17. Support for Technological Innovation in Medical Services
(1) Support enterprises in collaborating with hospitals, universities, and other institutions to establish new R&D entities such as technology innovation centers, research institutes, and testing platforms. Promote the application of technological innovations in the life sciences and health sector, including mobile healthcare, remote diagnosis, and smart hospitals. For projects that demonstrate significant industry or regional leadership and are replicable, financial support of 30% of the project investment will be provided, with a maximum of 5 million yuan per project.
(2) Support enterprises in strengthening cooperation with healthcare service providers in areas such as medical big data applications and precision medicine research. Encourage the development of innovative clinical applications and the clinical translation of products based on cutting-edge life sciences and health technologies, including next-generation sequencing, gene editing, synthetic biology, and regenerative medicine. Funding support of 30% of the project investment will be provided, with a maximum of 3 million yuan per project.
(IV) Prioritize Support for the Cellular Diagnosis and Therapy, Genetic Diagnosis and Therapy, Innovative Vaccines, and Innovative Medical Devices Sectors
18. For high-end biopharmaceutical manufacturers specializing in cellular and gene-based diagnostic and therapeutic products that establish operations in Baoshan District, as well as manufacturers of innovative vaccines and medical devices that establish operations in recognized municipal-level specialized industrial parks, additional priority support will be provided if their projects constitute major innovations and possess independent intellectual property rights.
19. For key enterprises within the district operating in the four major sub-sectors—cell-based diagnostic and therapeutic products, gene-based diagnostic and therapeutic products, innovative vaccines, and innovative medical devices—projects focused on core technology R&D (or possessing core technological capabilities) and key industrialization projects will receive matching support at a 1:1 ratio based on municipal-level funding.
20. For key enterprises within the four major sub-sectors—cell-based diagnostic and therapeutic products, gene-based diagnostic and therapeutic products, innovative vaccines, and innovative medical devices—in the district, those leasing production and office space will receive support equivalent to 80% of the total rent (for up to 3 years), with a maximum of 5 million yuan; those purchasing production and office space for their own use will receive support of up to 10 million yuan.
21. For high-end biological product manufacturers specializing in cellular diagnosis and therapy or genetic diagnosis and therapy that establish operations in Baoshan District, as well as manufacturers of innovative vaccines and innovative medical devices that establish operations in recognized municipal-level specialized parks, expenses incurred during the completion of environmental impact assessment procedures, feasibility studies, and project construction plans will be supported at 50% of actual expenditures (up to 200,000 yuan) after the project passes final inspection, is filed, and begins operations.
22. For high-end biological product manufacturers specializing in cell-based diagnostic and therapeutic products or gene-based diagnostic and therapeutic products that establish operations in Baoshan District, as well as innovative vaccine and medical device manufacturers that establish operations in recognized municipal-level specialized industrial parks, a one-time reward of 250,000 yuan will be granted upon obtaining high-tech enterprise certification.
(V) Support for Obtaining Professional Accreditation
23. Enterprises or institutions obtaining certification for the first time from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), the World Health Organization (WHO), the Ethics Committee for the Asia-Pacific Region (FERCAP/SIDCER), or the Association for the Accreditation of Human Research Protection Programs (AAHRPP) will receive support equivalent to 20% of the actual certification costs incurred, up to a maximum of 2 million yuan; the annual maximum for a single enterprise is 10 million yuan.
24. Medical institutions in Baoshan District that complete the filing process for medical device or drug clinical trial institutions will receive a reward of up to 5 million yuan. For medical institutions that have already completed such filings, an additional 300,000 yuan or 500,000 yuan will be awarded for each new specialized discipline added to their medical device or drug clinical trial institution filings, respectively; the cumulative reward for each institution shall not exceed 10 million yuan.
25. Support the entry of private capital into the healthcare services sector. Encourage privately-run medical institutions to actively participate in medical institution grading evaluations; provide a one-time reward of up to 5 million yuan to privately-run medical institutions newly awarded Grade III Class A accreditation.
(VI) Support for the Establishment of Institutional Platforms
26. Support the construction of key platforms in the biopharmaceutical industry. For newly established industry-leading Contract Research Organizations (CROs),Contract Manufacturing Organizations (CMOs), Contract Development and Manufacturing Organizations (CDMOs), third-party testing service platforms for drugs and medical devices, digital platforms for pharmaceutical equipment and technical quality traceability, clinical research application centers for medical big data, technological innovation service platforms and specialized service platforms for the health industry, and pharmaceutical industrial waste treatment facilities—public service platforms for the biopharmaceutical and life sciences sectors—the platform operator will receive support equivalent to 30% of the project investment, up to a maximum of 20 million yuan;For platforms that are already operational, support will be provided to encourage them to offer specialized biopharmaceutical R&D and manufacturing services to enterprises within the district (provided there is no investment affiliation with the platform), at a rate of 10% of the verified actual service revenue, with a maximum of 8 million yuan per platform per year.
27. Promoting the Construction of Key Laboratories
(1) Biopharmaceutical enterprises are encouraged to collaborate with universities, hospitals, and research institutions to establish key laboratories that can drive basic research and high-level academic exchange. Key laboratories recognized by the municipal competent authorities will receive support of up to 40 million yuan from both the municipal and district levels.
(2) Encourage the establishment of biosafety laboratories to conduct animal infection and pathogenic microorganism experiments. For biosafety laboratories that have been accredited by the China National Accreditation Service for Conformity Assessment (CNAS) and have commenced operations, support will be provided at 30% of the project investment, up to a maximum of 8 million yuan.
(7) Support the Establishment of Supporting Service Mechanisms
28. Support the Baoshan District Biomedical Expert Advisory Committee and the North Shanghai Biomedical Industry Alliance in playing an active role
(1) Encourage these two organizations to hold annual activities related to biomedicine and life sciences, such as policy consultation, professional training, and academic exchanges, and provide support based on actual expenses incurred, up to a maximum of 2 million yuan.
(2) Encourage these two organizations to host high-profile forums, exhibitions, and other events related to biomedicine and life sciences. Support will be provided at 50% of the actual expenses incurred for such events, up to a maximum of 2 million yuan.
29. Establish a Financial Service Platform
(1) Fully leverage the role of the District Science and Technology Innovation Industry Fund and explore the establishment of a Baoshan District Biomedical and Life Sciences Special Sub-Fund to support high-quality biomedical and life sciences projects based in Baoshan.
(2) Provide a 100% premium subsidy to eligible small, medium, and micro-sized biopharmaceutical enterprises that obtain guaranteed loans from the Shanghai Policy-based Financing Guarantee Fund Management Center for Small and Medium-sized Enterprises in the current year.
30. Strengthening the Shanghai Biomedical Product Registration Guidance Service Station (Baoshan). Provide enterprises with one-stop services including license registration, technical guidance, and regulatory consultation; further improve the regulatory facilitation system for imported biomedical R&D samples and fully implement the “single declaration, phased clearance” customs clearance model; explore the establishment of public bonded warehouses to reduce enterprise costs.
31. Promote the inclusion of translation projects from clinical research centers within the district’s medical institutions into the medical insurance coverage; promote the inclusion of innovative chemical drugs, generic chemical drugs, and traditional Chinese patent medicines developed and produced by biopharmaceutical enterprises within the district into the National Medical Insurance Drug Directory;Promote the inclusion of innovative medical devices developed by local medical and pharmaceutical enterprises in the dynamically adjusted catalog of medical devices eligible for separate billing, in accordance with regulations, while simultaneously establishing supporting fee and medical insurance reimbursement policies; promote the pilot inclusion of “Internet+” medical services within the district into medical insurance reimbursement; encourage local medical consumables to participate in centralized procurement in accordance with the municipal bureau’s principles of “volume-based pricing, categorized procurement, comprehensive price differentials, coordinated reimbursement, and the integration of medical services, medical insurance, and pharmaceuticals.”
(8) Support the Construction of Biopharmaceutical Incubators and Accelerators
32. For newly introduced biopharmaceutical incubators that lease office space within the district, support will be provided equivalent to 80% of the total rent (for up to 3 years), with a maximum of 5 million yuan.
33. Biomedical incubators included in Shanghai’s carrier cultivation system will receive a 500,000 yuan reward, while those recognized as national-level science and technology enterprise incubators will receive a 1 million yuan reward. Biomedical incubators that receive an annual performance evaluation of “excellent” (or higher) from the municipal science and technology authorities will be granted a matching reward equal to twice the municipal reward amount.
34. For each biopharmaceutical enterprise that graduates from a biopharmaceutical incubator and establishes operations in Baoshan, the incubator will receive a reward of 100,000 yuan per enterprise. If the graduated enterprise operates in Baoshan for at least two years and achieves profitability, the incubator will receive an additional 100,000 yuan per enterprise upon application.
35. If an incubated biopharmaceutical enterprise successfully goes public within five years of graduation and registers its headquarters in Baoshan District, a one-time reward of 1 million yuan will be granted to the incubator where the enterprise resided for at least two years.
36. Biopharmaceutical accelerators shall receive support equivalent to that provided under Articles 32–35 of this policy.
37. For district-level biomedical R&D and translation functional platforms that have been recognized, funding of up to 50% of project expenditures will be provided, with a maximum of 10 million yuan; for Shanghai-level R&D and translation functional platforms that have been recognized, support will be further increased.
(IX) Support for Attracting High-Level Talent
38. Accelerate the recruitment of high-end talent. High-level talent recruited by biopharmaceutical and life sciences enterprises will be eligible for housing settlement subsidies of up to 2 million yuan; a direct contribution reward for high-end biopharmaceutical talent will be implemented, with eligible individuals receiving up to 100,000 yuan; efforts to recruit high-end biopharmaceutical talent from overseas will be intensified, with employment assistance and startup funding provided to international students and foreign nationals, and special funding granted to those who meet the criteria; support for eligible high-end talent in areas such as residency registration and talent apartments will be strengthened.
39. Strengthen housing security for talent. Newly recruited biomedical and life sciences innovation talent who do not own their own housing in Baoshan District and meet relevant criteria may apply to rent talent apartments; those who qualify may apply for rental subsidies of up to 2,000 yuan per person per month.
40. Optimize the innovation and entrepreneurship environment. For outstanding talent in the biomedicine and life sciences sectors who establish enterprises in Baoshan with their own technologies or projects, arrangements will be made for them to move into relevant specialized parks within the district, and subsidies will be provided for the rental of office space or industrial facilities; subsidies will be provided for the establishment of outstanding startup projects, supplementary interest subsidies for startup guarantee loans, and venue rental costs; outstanding projects that win awards in district-level or higher innovation and entrepreneurship competitions and settle in Baoshan will receive 200,000 yuan in support.
41. Support targeted talent training programs. Encourage local biopharmaceutical and life sciences enterprises to collaborate with relevant universities, research institutes, and vocational colleges to cultivate professional technical talent. Local enterprises that recruit professional technical talent through customized commissioned training programs will receive up to 500,000 yuan in support.
(X) Support for Green Development
42. Standardize the collection, sorting, temporary storage, and disposal of hazardous waste. For small and medium-sized enterprises engaged in biopharmaceutical R&D and production, provide support equivalent to 50% of hazardous waste disposal costs, up to a maximum of 50,000 yuan per enterprise annually, for a period of three years.
43. Encourage the establishment of hazardous waste disposal facilities. For newly established hazardous waste disposal units within specialized industrial parks, upon obtaining a hazardous waste operating license, support will be provided equivalent to 50% of the project investment, up to a maximum of 1.5 million yuan. For enterprise-led hazardous waste self-utilization and disposal construction projects, upon successful acceptance, support will be provided equivalent to 30% of the project investment, up to a maximum of 1 million yuan.
III. Supplementary Provisions
(1) The Baoshan District Economic Commission is responsible for interpreting this policy.
(2) This policy shall take effect on the date of issuance and remain valid until December 31, 2024.
